Literature DB >> 15477371

Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning.

Allen D Seftel1, Randall J Mack, Allen R Secrest, Ted M Smith.   

Abstract

It is recognized that testosterone (T) levels decrease in men with age, as does sexual function. We hypothesize that T supplementation in hypogonadal men with sexual dysfunction will restore certain elements of sexual function. Hypogonadal male subjects (total T < or = 300 ng/dL, n = 406, mean age 58 years) reporting one or more symptoms of low testosterone were randomized to T gel (50 mg/d and 100 mg/d), T patch, or placebo. Twenty-four-hour pharmacokinetic profiles for T were obtained. The 3 primary end points evaluated at 30 and 90 days posttreatment included a significant change in the frequency of intercourse and nighttime erections per 7-day week as well as a change in sexual desire measured on a Likert-type scale and calculated as a mean daily score. At day 30, a significant increase from baseline in sexual desire was noted for those on 100 mg/d T gel compared with those on 50 mg/d T gel, T patch, or placebo (1.2 vs 0.4, 0.7, and 0.4, respectively). A significant increase from baseline in the frequency of nighttime erections was also noted for those on 100 mg/d T gel compared with those on 50 mg/d T gel or placebo (51% of subjects in the 100 mg/d T gel group had an increase in frequency vs 30% for the 50 mg/d T gel group and 26% in the placebo group). Finally, a significant increase from baseline in the frequency of intercourse was evidenced for those on 100 mg/d T gel compared with those on T patch or placebo (39% of subjects in the 100 mg/d T gel group had an increase in frequency vs 21% for the T patch group and 24% in the placebo group). Similar results were seen for 100 mg/d T gel at day 90 for sexual desire and nighttime erections vs placebo. These data demonstrate a clear relationship between restoring serum T concentrations and improvement in certain parameters of sexual function. We propose that threshold T levels are needed in order to significantly affect improvements in sexual functioning.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477371     DOI: 10.1002/j.1939-4640.2004.tb03169.x

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  14 in total

Review 1.  [Is there a pharmacotherapy for libido disturbances in men?].

Authors:  F-M Köhn
Journal:  Urologe A       Date:  2006-08       Impact factor: 0.639

2.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

3.  Increased sexual desire with exogenous testosterone administration in men with obstructive sleep apnea: a randomized placebo-controlled study.

Authors:  K L Melehan; C M Hoyos; B J Yee; K K Wong; P R Buchanan; R R Grunstein; P Y Liu
Journal:  Andrology       Date:  2015-11-26       Impact factor: 3.842

4.  Pharmacologically induced hypogonadism and sexual function in healthy young women and men.

Authors:  Peter J Schmidt; Emma M Steinberg; Paula Palladino Negro; Nazli Haq; Carolyn Gibson; David R Rubinow
Journal:  Neuropsychopharmacology       Date:  2008-03-19       Impact factor: 7.853

Review 5.  Significance of hypogonadism in erectile dysfunction.

Authors:  Jacques Buvat; Gilbert Bou Jaoudé
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

6.  Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management.

Authors:  Marco de Tubino Scanavino
Journal:  Adv Urol       Date:  2011-10-20

7.  Partial androgen deficiency, depression, and testosterone supplementation in aging men.

Authors:  Mario Amore; Marco Innamorati; Sara Costi; Leo Sher; Paolo Girardi; Maurizio Pompili
Journal:  Int J Endocrinol       Date:  2012-06-07       Impact factor: 3.257

8.  Testosterone and vascular function in aging.

Authors:  Rhéure A M Lopes; Karla B Neves; Fernando S Carneiro; Rita C Tostes
Journal:  Front Physiol       Date:  2012-04-10       Impact factor: 4.566

Review 9.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 10.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.